Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
Collegium to Participate in Upcoming Investor Conferences
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
Head to Head Contrast: Collegium Pharmaceutical (NASDAQ:COLL) versus electroCore (NASDAQ:ECOR)
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Collegium to Present New Real-World Data at PainConnect 2026
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below 50 Day Moving Average – Here’s What Happened
Analyzing Collegium Pharmaceutical (NASDAQ:COLL) and Pivotal Therapeutics (OTCMKTS:PVTTF)
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC
Collegium Pharmaceutical: Buying The Projected Growth For 2026
SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
Collegium Provides 2026 Financial Guidance and Business Update
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month High – Here’s What Happened
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Assenagon Asset Management S.A. Purchases 92,898 Shares of Collegium Pharmaceutical, Inc. $COLL
Best Value Stocks to Buy for Dec. 18
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?
Ensign Peak Advisors Inc Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL
Ballast Asset Management LP Makes New Investment in Collegium Pharmaceutical, Inc. $COLL
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Advantage Alpha Capital Partners LP
Why 2025 is a Dynamic and Transformative Year for Collegium
Bank of New York Mellon Corp Grows Stake in Collegium Pharmaceutical, Inc. $COLL